{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:13:18Z","timestamp":1770747198051,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Objective<\/jats:title>\n This study aimed to analyse the variation of circulating tumour DNA (ctDNA) in patients with hepatocellular carcinoma (HCC).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Newly diagnosed patients with HCC admitted between March 2022 and October 2023 were prospectively enrolled. Plasma ctDNA testing was performed before treatment, and clinical information, treatment regimens and survival data were collected.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 166 patients with HCC were enrolled, including 127 men and 39 women, with a mean age of 58.1\u00b110.0 years. Of these, 137 patients were infected with hepatitis B virus, and 129 had underlying cirrhosis. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, 74, 20, 52 and 20 patients were classified as stages A, B, C and D, respectively. Tumour mutation burden (TMB) ranged from 0 to 35.48 mutations per Mb; it increased with higher BCLC stages but decreased in stage D. The top five mutated genes were\n TP53<\/jats:italic>\n (39.8%),\n CTNNB1<\/jats:italic>\n (15.7%),\n LRP1B<\/jats:italic>\n (12.0%),\n ARID1A<\/jats:italic>\n (10.8%) and\n FAT3<\/jats:italic>\n (9.0%). Patients with\n TP53<\/jats:italic>\n and\n LRP1B<\/jats:italic>\n mutations exhibited shorter survival (\n p<\/jats:italic>\n &lt; 0.05). Among the 54 patients who received systemic therapy, only those with\n LRP1B<\/jats:italic>\n mutations had significantly reduced overall survival (OS) (\n p<\/jats:italic>\n = 0.048). Cox multivariate survival analysis revealed that TMB and Child\u2013Pugh scores were closely associated with OS. Regardless of tumour stage,\n LRP1B<\/jats:italic>\n mutation was significantly correlated with OS in patients undergoing systemic therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Circulating tumour DNA testing demonstrated that TMB is closely associated with OS in patients with HCC. Patients with HCC with\n LRP1B<\/jats:italic>\n mutations had significantly shorter survival when receiving systemic therapy. Circulating tumour DNA testing holds considerable value in predicting HCC prognosis and may serve as a biomarker for assessing patient outcomes.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2025.1653475","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:21:38Z","timestamp":1770700898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis between plasma circulating tumour deoxyribonucleic acid variations and survival in patients with hepatocellular carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Songtao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13046-018-0893-1","article-title":"Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA","volume":"37","author":"Li","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.781820","article-title":"Clinical applications of liquid biopsy in hepatocellular carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2799","article-title":"Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2312246","article-title":"The assessment of circulating tumor DNA associated with Wnt\/\u03b2-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0426","article-title":"Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment","volume":"30","author":"Sogbe","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13046-021-02016-3","article-title":"Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib","volume":"40","author":"Fujii","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3341","article-title":"Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA","volume":"25","author":"Kaseb","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.48983","article-title":"LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13105","article-title":"Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study","volume":"16","author":"Zhu","year":"2022","journal-title":"Mol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0479","article-title":"Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma","volume":"23","author":"Ikeda","year":"2018","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101073","article-title":"Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma","volume":"14","author":"Ge","year":"2021","journal-title":"Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143367","article-title":"Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy","volume":"14","author":"Matsumae","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0762-5","article-title":"Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples","volume":"122","author":"Mankor","year":"2020","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2907243","article-title":"TMB signature-related RCAN2 promotes apoptosis by upregulating EHF\/DR5 pathway in hepatocellular carcinoma","volume":"29","author":"Xu","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006386","article-title":"Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance","volume":"280","author":"Wehrle","year":"2024","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205980","article-title":"Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring","volume":"16","author":"Yang","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B21","article-title":"Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma","volume":"11","author":"He","year":"2019","journal-title":"Am J Transl Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2019.04.014","article-title":"Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma","volume":"116","author":"Howell","year":"2019","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12032-022-01726-8","article-title":"RNA splicing: a dual-edged sword for hepatocellular carcinoma","volume":"39","author":"Kashyap","year":"2022","journal-title":"Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2015.06.009","article-title":"Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy","volume":"1","author":"Ono","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06962-1","article-title":"Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study","volume":"49","author":"Pommergaard","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/s41467-022-33351-4","article-title":"The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1038\/s41467-021-26213-y","article-title":"Cancer gene mutation frequencies for the U.S. population","volume":"12","author":"Mendiratta","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.10.021","article-title":"LRP1B suppresses HCC progression through the NCSTN\/PI3K\/AKT signaling axis and affects doxorubicin resistance","volume":"10","author":"Zhai","year":"2022","journal-title":"Genes Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2060778","article-title":"Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway","volume":"13","author":"Zhen","year":"2022","journal-title":"Bioengineered"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e29763","DOI":"10.1097\/MD.0000000000029763","article-title":"LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma","volume":"101","author":"Yu","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S348785","article-title":"LRP1B is a potential biomarker for tumor immunogenicity and prognosis of HCC patients receiving ICI treatment","volume":"9","author":"Cheng","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1770","article-title":"Morphometric analysis of mast cells in tumor predicts recurrence of hepatocellular carcinoma after liver transplantation","volume":"5","author":"Rohr-Udilova","year":"2021","journal-title":"Hepatol Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7150\/jca.53124","article-title":"LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma","volume":"12","author":"Liu","year":"2021","journal-title":"J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1653475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:21:39Z","timestamp":1770700899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1653475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1653475"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1653475","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1653475"}}